{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:43:24Z","timestamp":1789469004674,"version":"build-2803163510"},"reference-count":109,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jscai.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Society for Cardiovascular Angiography &amp; Interventions"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jscai.2026.105568","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:21:45Z","timestamp":1785835305000},"page":"105568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter-2 Inhibitors in Valvular Heart Disease: From Mechanistic Insights to Clinical Application"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5232-5147","authenticated-orcid":false,"given":"Haytham","family":"Allaham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-9125","authenticated-orcid":false,"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloke","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Alhaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jscai.2026.105568_bib1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jscai.2026.105568_bib2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jscai.2026.105568_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jscai.2026.105568_bib5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jscai.2026.105568_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2023.04.002","article-title":"The effect of sodium\u2013glucose cotransporter-2 inhibitors on cardiac structural remodeling and function: a meta-analysis of randomized controlled trials","volume":"114","author":"Fan","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"18","key":"10.1016\/j.jscai.2026.105568_bib7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jscai.2026.105568_bib8","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jscai.2026.105568_bib9","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter repair for patients with tricuspid regurgitation","volume":"388","author":"Sorajja","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jscai.2026.105568_bib10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.echo.2012.06.010","article-title":"Early regression of left ventricular mass associated with diastolic improvement after transcatheter aortic valve implantation","volume":"25","author":"Vizzardi","year":"2012","journal-title":"J Am Soc Echocardiogr"},{"issue":"16","key":"10.1016\/j.jscai.2026.105568_bib11","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jacc.2010.11.043","article-title":"The acute hemodynamic effects of MitraClip therapy","volume":"57","author":"Siegel","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jscai.2026.105568_bib12","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.3390\/ijms26136322","article-title":"Right ventricular dynamics in tricuspid regurgitation: insights into reverse remodeling and outcome prediction post transcatheter valve intervention","volume":"26","author":"Doldi","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib13","first-page":"632","article-title":"Mechanisms of cardiovascular benefits of sodium\u2013glucose cotransporter 2 inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101285","article-title":"The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection","volume":"47","author":"Delanaye","year":"2021","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.jscai.2026.105568_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/imj.14260","article-title":"Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study","volume":"49","author":"Cohen","year":"2019","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.jscai.2026.105568_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.jscai.2026.105568_bib17","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/s41440-025-02216-w","article-title":"Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states","volume":"48","author":"Katsurada","year":"2025","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor\u2013induced sympathoinhibition","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Subanalysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium\u2013glucose cotransporter-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized controlled trials with 22,528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.013481","article-title":"Use of SGLT2 (sodium\u2013glucose cotransporter 2) inhibitors in pulmonary hypertension","volume":"19","author":"Aguado","year":"2026","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium\u2013glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.jscai.2026.105568_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4110\/in.2016.16.1.26","article-title":"Involvement of immune cell network in aortic valve stenosis: communication between valvular interstitial cells and immune cells","volume":"16","author":"Lee","year":"2016","journal-title":"Immune Netw"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/CIRCINTERVENTIONS.112.971028","article-title":"Cellular mechanisms of aortic valve calcification","volume":"5","author":"Leopold","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12026-017-8978-z","article-title":"T cell subsets: an integral component in pathogenesis of rheumatic heart disease","volume":"66","author":"Toor","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.jscai.2026.105568_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors\u2014do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.jscai.2026.105568_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110642","article-title":"Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway","volume":"501","author":"Lu","year":"2020","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/1440-1681.13638","article-title":"Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK\/SIRT1 activation","volume":"49","author":"Faridvand","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jscai.2026.105568_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.jscai.2026.105568_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome\u2013mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41401-023-01217-0","article-title":"Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation","volume":"45","author":"Li","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jscai.2026.105568_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jscai.2026.105568_bib34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jscai.2026.105568_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2022.03.005","article-title":"Blocking the NLRP3 inflammasome reduces osteogenic calcification and M1 macrophage polarization in a mouse model of calcified aortic valve stenosis","volume":"347","author":"Lu","year":"2022","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","article-title":"Role of oxidative stress in cardiac hypertrophy and remodeling","volume":"49","author":"Takimoto","year":"2007","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.jscai.2026.105568_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacbts.2024.02.012","article-title":"Human aortic stenotic valve\u2013derived extracellular vesicles induce endothelial dysfunction and thrombogenicity through the AT1R\/NADPH oxidases\/SGLT2 pro-oxidant pathway","volume":"9","author":"Hmadeh","year":"2024","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.jscai.2026.105568_bib38","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.7150\/thno.71813","article-title":"The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications","volume":"12","author":"Phua","year":"2022","journal-title":"Theranostics"},{"issue":"10-11","key":"10.1016\/j.jscai.2026.105568_bib39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.clinbiochem.2009.04.012","article-title":"Increased serum oxidative stress in patients with severe mitral regurgitation: a new finding and potential mechanism for atrial enlargement","volume":"42","author":"Chen","year":"2009","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/MAJ.0b013e318224ab93","article-title":"Oxidative stress and myocardial remodeling in chronic mitral regurgitation","volume":"342","author":"Gladden","year":"2011","journal-title":"Am J Med Sci"},{"issue":"suppl 1","key":"10.1016\/j.jscai.2026.105568_bib41","article-title":"Relationship between oxidative stress and three-dimensional echocardiographic changes in myxomatous mitral valves with severe regurgitation: a pilot study","volume":"23","author":"Sosdean","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib42","article-title":"Chronic pressure overload results in deficiency of mitochondrial membrane transporter ABCB7 which contributes to iron overload, mitochondrial dysfunction, metabolic shift and worsens cardiac function","volume":"9","author":"Kumar","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jscai.2026.105568_bib43","first-page":"1212","article-title":"The role of mitochondrial dysfunction and dynamics in hypertensive heart disease: mechanisms and recent advances","volume":"14","author":"Mweene","year":"2025","journal-title":"Biology (Basel)"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacbts.2019.10.004","article-title":"Celastrol alleviates aortic valve calcification via inhibition of NADPH oxidase 2 in valvular interstitial cells","volume":"5","author":"Liu","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"13","key":"10.1016\/j.jscai.2026.105568_bib45","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.3390\/ijms23137142","article-title":"Blocking of SGLT2 to eliminate NADPH-induced oxidative stress in lenses of animals with fructose-induced diabetes mellitus","volume":"23","author":"Chen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jscai.2026.105568_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708177","article-title":"A SGLT2 inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro","volume":"12","author":"Xing","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00018-025-05793-8","article-title":"Dapagliflozin alleviates mitochondrial damage in the myocardium under diabetic conditions by targeting sortilin","volume":"82","author":"Gao","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jscai.2026.105568_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/MSMBR.907775","article-title":"Phlorizin exerts direct protective effects on palmitic acid\u2013induced endothelial dysfunction by activating the PI3K\/AKT\/eNOS signaling pathway and increasing nitric oxide levels","volume":"24","author":"Li","year":"2018","journal-title":"Med Sci Monit Basic Res"},{"issue":"8","key":"10.1016\/j.jscai.2026.105568_bib49","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/antiox10081166","article-title":"Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases","volume":"10","author":"Tsai","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jscai.2026.105568_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112169","article-title":"Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress\u2013associated mechanisms in heart failure","volume":"143","author":"Gager","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jscai.2026.105568_bib51","first-page":"689","article-title":"Endoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseases","volume":"13","author":"Liu","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib52","first-page":"1652","article-title":"Endoplasmic reticulum stress associated apoptosis implicated in atrial fibrillation","volume":"9","author":"Chen","year":"2016","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"10.1016\/j.jscai.2026.105568_bib53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd3976","article-title":"Targeting the unfolded protein response in disease","volume":"12","author":"Hetz","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117567","article-title":"The ER stress-mediated mitochondrial apoptotic pathway and MAPKs modulate tachypacing-induced apoptosis in HL-1 atrial myocytes","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cstres.2023.12.003","article-title":"Endoplasmic reticulum stress-mediated cell death in cardiovascular disease","volume":"29","author":"An","year":"2024","journal-title":"Cell Stress Chaperones"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib56","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1159\/000475942","article-title":"The sodium\u2013glucose cotransporter 2 inhibitor empagliflozin protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway","volume":"41","author":"Zhou","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib57","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1038\/s41598-019-46402-6","article-title":"Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death","volume":"9","author":"Shibusawa","year":"2019","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.jscai.2026.105568_bib58","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019274","article-title":"Dapagliflozin improves cardiac hemodynamics and mitigates arrhythmogenesis in mitral regurgitation\u2013induced myocardial dysfunction","volume":"10","author":"Lin","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.jscai.2026.105568_bib59","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1113\/JP273879","article-title":"Compensatory and decompensatory alterations in cardiomyocyte Ca2+ dynamics in hearts with diastolic dysfunction following aortic banding","volume":"595","author":"Gattoni","year":"2017","journal-title":"J Physiol"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib60","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x202010138","article-title":"Calcium homeostasis behavior and cardiac function on left ventricular remodeling by pressure overload","volume":"54","author":"Mazeto","year":"2021","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib61","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: mechanisms: part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jscai.2026.105568_bib62","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.3390\/ijms25137274","article-title":"Endothelial protection by sodium\u2013glucose cotransporter 2 inhibitors: a literature review of in vitro and in vivo studies","volume":"25","author":"Mylonas","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"16","key":"10.1016\/j.jscai.2026.105568_bib64","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jscai.2026.105568_bib65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10557-022-07377-1","article-title":"The SGLT2 inhibitor dapagliflozin reduces right ventricular mass independent of changes in right ventricular pressure induced by pulmonary artery banding","volume":"38","author":"Connelly","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-022-01614-5","article-title":"Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling","volume":"21","author":"Wu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jscai.2026.105568_bib68","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3389\/fphys.2020.00912","article-title":"Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction","volume":"11","author":"Peng","year":"2020","journal-title":"Front Physiol"},{"issue":"13","key":"10.1016\/j.jscai.2026.105568_bib69","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.107.653584","article-title":"Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure","volume":"117","author":"Haddad","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jscai.2026.105568_bib70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/01.RES.0000136520.07995.aa","article-title":"Valvular myofibroblast activation by transforming growth factor-\u03b2: implications for pathological extracellular matrix remodeling in heart valve disease","volume":"95","author":"Walker","year":"2004","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib71","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2011-09-377648","article-title":"Platelet TGF-\u03b21 contributions to plasma TGF-\u03b21, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload","volume":"119","author":"Meyer","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jscai.2026.105568_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008476","article-title":"Plasma levels of transforming growth factor-beta1 reflect left ventricular remodeling in aortic stenosis","volume":"4","author":"Villar","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jscai.2026.105568_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ppedcard.2021.101347","article-title":"Circulating transforming growth factor-beta levels and myocardial remodeling in young adults with mitral valve prolapse patients","volume":"62","author":"Malev","year":"2021","journal-title":"Prog Pediatr Cardiol"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3346\/jkms.2008.23.1.41","article-title":"Overexpression of transforming growth factor-\u03b21 in the valvular fibrosis of chronic rheumatic heart disease","volume":"23","author":"Kim","year":"2008","journal-title":"J Korean Med Sci"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib75","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: the BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jscai.2026.105568_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122354","article-title":"Empagliflozin protects against isoprenaline-induced fibrosis in rat heart through modulation of TGF-\u03b2\/SMAD pathway","volume":"337","author":"Elsayed","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.jscai.2026.105568_bib77","article-title":"Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-\u03b21\/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"issue":"16","key":"10.1016\/j.jscai.2026.105568_bib78","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.jscai.2026.105568_bib79","first-page":"6887","article-title":"Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts","volume":"17","author":"Meng","year":"2018","journal-title":"Mol Med Rep"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib80","first-page":"543","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl Sci"},{"issue":"5","key":"10.1016\/j.jscai.2026.105568_bib82","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajh\/hpz016","article-title":"Dapagliflozin attenuates cardiac remodeling in a mouse model of cardiac pressure overload","volume":"32","author":"Shi","year":"2019","journal-title":"Am J Hypertens"},{"issue":"19","key":"10.1016\/j.jscai.2026.105568_bib83","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/heartjnl-2017-311506","article-title":"The role and clinical implications of diastolic dysfunction in aortic stenosis","volume":"103","author":"Kampaktsis","year":"2017","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib84","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jcin.2018.01.240","article-title":"The impact of left ventricular diastolic dysfunction on clinical outcomes after transcatheter aortic valve replacement","volume":"11","author":"Asami","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib85","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jcin.2024.11.036","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on the progression of aortic stenosis","volume":"18","author":"Shah","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib86","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/jcm15020714","article-title":"Assessing potential valve-preserving effects of SGLT2 inhibitors in degenerative aortic stenosis: a propensity-matched study","volume":"15","author":"Morel","year":"2026","journal-title":"J Clin Med"},{"issue":"24","key":"10.1016\/j.jscai.2026.105568_bib87","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.124.069144","article-title":"Ertugliflozin for functional mitral regurgitation associated with heart failure: EFFORT trial","volume":"149","author":"Kang","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib88","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/ehf2.15296","article-title":"Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial","author":"Huang","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"18","key":"10.1016\/j.jscai.2026.105568_bib89","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.3390\/jcm12185898","article-title":"Effect of dapagliflozin on patients with rheumatic heart disease mitral stenosis","volume":"12","author":"Asrial","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jscai.2026.105568_bib90","first-page":"186","article-title":"Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes","volume":"12","author":"Loutati","year":"2026","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib91","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.125.015398","article-title":"Prediction of heart failure hospitalization or death after TAVR","volume":"19","author":"El-Sabawi","year":"2026","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.jscai.2026.105568_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.shj.2023.100187","article-title":"Outcomes of thirty-day readmission in patients with heart failure on index hospitalization undergoing transcatheter edge-to-edge mitral repair: insights from the United States Nationwide Readmission Database","volume":"7","author":"Zahid","year":"2023","journal-title":"Struct Heart"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102462","article-title":"Sodium glucose co-transporter 2 inhibitors in patients with heart failure and transcatheter aortic valve replacement","volume":"5","author":"Yasmin","year":"2026","journal-title":"JACC Adv"},{"issue":"1","key":"10.1016\/j.jscai.2026.105568_bib94","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","article-title":"SGLT2 inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)","volume":"23","author":"Paolisso","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"14","key":"10.1016\/j.jscai.2026.105568_bib95","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jscai.2026.105568_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101750","article-title":"The association between sodium\u2013glucose cotransporter 2 inhibitors and bioprosthetic aortic valve degeneration","volume":"4","author":"Abbas","year":"2025","journal-title":"JACC Adv"},{"issue":"18 Suppl","key":"10.1016\/j.jscai.2026.105568_bib97","first-page":"B9","article-title":"Clinical outcomes of SGLT2 inhibitors among patients undergoing mitral transcatheter edge-to-edge repair","volume":"84","author":"Thakkar","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jscai.2026.105568_bib98","first-page":"B-55","article-title":"Impact of SGLT2 inhibitors on clinical outcomes in patients with heart failure with reduced ejection fraction and mitral regurgitation undergoing transcatheter edge-to-edge repair","volume":"4","author":"Ajenaghughrure","year":"2025","journal-title":"JSCAI"},{"key":"10.1016\/j.jscai.2026.105568_bib99","article-title":"SGLT inhibitors in patients undergoing tricuspid valve transcatheter edge-to-edge repair","author":"Kumar","year":"2025","journal-title":"Am J Ther"},{"key":"10.1016\/j.jscai.2026.105568_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777083","article-title":"Effects of sodium\u2013glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease treated by coronary artery bypass grafting via MiECC: inflammatory burden and clinical outcomes at 5 years of follow-up","volume":"12","author":"Sardu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib101","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1213\/ANE.0000000000007705","article-title":"Impact of sodium\u2013glucose cotransporter-2 inhibitors on cardiovascular outcomes after cardiac surgery: a pilot study","volume":"142","author":"Labaste","year":"2026","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.jscai.2026.105568_bib102","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/a-2616-4962","article-title":"Impact of SGLT2 inhibitor therapy on patients undergoing cardiac surgery","volume":"74","author":"Taghiyev","year":"2026","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jscai.2026.105568_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2025.111811","article-title":"The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: an open-label randomized pilot study","volume":"103","author":"Snel","year":"2025","journal-title":"J Clin Anesth"},{"issue":"12 Suppl","key":"10.1016\/j.jscai.2026.105568_bib104","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.jvca.2025.09.183","article-title":"Perioperative administration of SGLT2 inhibitors in non-diabetic cardiac surgery patients with heart failure: friend or foe?","volume":"39","author":"Hassan","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"2","key":"10.1016\/j.jscai.2026.105568_bib105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bja.2024.05.004","article-title":"Risk of perioperative discontinuation of SGLT2 inhibitors","volume":"133","author":"Oosterom-Eijmael","year":"2024","journal-title":"Br J Anaesth"},{"issue":"10","key":"10.1016\/j.jscai.2026.105568_bib106","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1053\/j.jvca.2022.06.008","article-title":"Euglycemic diabetic ketoacidosis associated with sodium\u2013glucose cotransporter-2 inhibitors after cardiac surgery: a review of current literature","volume":"36","author":"Branco","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"7","key":"10.1016\/j.jscai.2026.105568_bib107","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1053\/j.jvca.2022.02.019","article-title":"SGLT-2 inhibitors: proliferating indications and perioperative pitfall","volume":"36","author":"Madhok","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"16","key":"10.1016\/j.jscai.2026.105568_bib108","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jscai.2026.105568_bib109","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamasurg.2025.0940","article-title":"Postoperative outcomes among sodium\u2013glucose cotransporter 2 inhibitor users","volume":"160","author":"Tallarico","year":"2025","journal-title":"JAMA Surg"}],"container-title":["Journal of the Society for Cardiovascular Angiography &amp; Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930326013153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930326013153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:21:55Z","timestamp":1789464115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772930326013153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2772930326013153"],"URL":"https:\/\/doi.org\/10.1016\/j.jscai.2026.105568","relation":{},"ISSN":["2772-9303"],"issn-type":[{"value":"2772-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-2 Inhibitors in Valvular Heart Disease: From Mechanistic Insights to Clinical Application","name":"articletitle","label":"Article Title"},{"value":"Journal of the Society for Cardiovascular Angiography & Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jscai.2026.105568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the Society for Cardiovascular Angiography & Interventions Foundation.","name":"copyright","label":"Copyright"}],"article-number":"105568"}}